Reynard Alison K, Sullivan Amy Burleson, Rae-Grant Alexander
Psychiatry and Psychology (AKR, ABS) and the Mellen Center for Multiple Sclerosis Treatment and Research (ABS, ARG), Cleveland Clinic, Cleveland, OH, USA. Dr. Reynard is now with NorthShore University HealthSystem, Evanston, IL, USA.
Int J MS Care. 2014 Fall;16(3):140-4. doi: 10.7224/1537-2073.2013-034.
The objective of this study was to identify stress-management interventions used for people with multiple sclerosis (MS) and systematically evaluate the efficacy of these interventions.
Several strategies were used to search for studies reported in articles published up to 2013.
Our initial search retrieved 117 publications, of which 8 met our criteria for review. Of the eight studies, one provided Class I evidence, five provided Class III evidence, and two provided Class IV evidence for the efficacy of stress-management interventions according to the evidence classification established by the American Academy of Neurology. Most studies showed positive changes in outcomes assessed; however, the range of methodological quality among the published studies made it difficult to draw conclusions.
The promising findings for stress-management interventions highlight the need for future studies. Additional large, prospective, multicenter studies will help to define the role of stress-management interventions in the treatment and course of MS. Furthermore, including outcome measures based on biological and clinical markers of disease will prove useful in understanding potential underlying mechanisms.
本研究的目的是确定用于多发性硬化症（MS）患者的压力管理干预措施，并系统评估这些干预措施的疗效。
采用多种策略检索截至2013年发表的文章中报道的研究。
我们最初的检索得到了117篇出版物，其中8篇符合我们的综述标准。根据美国神经病学学会制定的证据分类，在这八项研究中，一项提供了I类证据，五项提供了III类证据，两项提供了IV类证据以证明压力管理干预措施的疗效。大多数研究显示在评估的结果方面有积极变化；然而，已发表研究之间的方法学质量范围使得难以得出结论。
压力管理干预措施的有前景的研究结果凸显了未来研究的必要性。更多大型、前瞻性、多中心研究将有助于确定压力管理干预措施在MS治疗和病程中的作用。此外，纳入基于疾病生物学和临床标志物的结局指标将有助于理解潜在的潜在机制。
